MAP
PRTK

Moody Aldrich Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Moody Aldrich Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-54,394
Closed -$974K – 98
2017
Q4 		$974K Buy
54,394
+11,324
+26% +$236K 0.79% 60
2017
Q3 		$1.08M Buy
+43,070
New +$1M 1.11% 44

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Moody Aldrich Partners's PRTK Position: Q1 2018 in Review

Moody Aldrich Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2018, closing a stake of 54,394 shares — an estimated $974K sold.

Moody Aldrich Partners first reported a position in PRTK in Q3 2017 and held it in 2 quarters. The position peaked at $1.08M in Q3 2017. 114 funds tracked by Wall St. Rank hold PRTK as of Q1 2018.

  • Moody Aldrich Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Moody Aldrich Partners sold 54,394 Paratek Pharmaceuticals, Inc. shares in Q1 2018, an estimated $974K.
  • Moody Aldrich Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 2 quarters.
  • Moody Aldrich Partners's Paratek Pharmaceuticals, Inc. position peaked at $1.08M in Q3 2017.
  • 114 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2018.

Based on Moody Aldrich Partners's 13F filing for Q1 2018, filed 26 Apr 2018.